San Francisco, CA, United States of America

Hangil Park

This inventor holds 15 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Galaxy Biotech, LLC, Walking Fish Therapeutics, Five Prime Therapeutics, Inc.. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hangil Park. Retrieved from https://idiyas.com/inventor/hangil-park-efdl13jh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 8)

% Patents Active = 73.3

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 72(Granted Patents)

Location History:

San Francisco, CA (US) (2009 - 2024)
South San Francisco, CA (US) (2024)

Company Filing History:

Walking Fish Therapeutics

patents

1 out of 77

Five Prime Therapeutics, Inc.

patents

Years Active: 2009-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679897 - MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 (2026-07-14),

2. 12037604 - Modified B cells and methods of use thereof (2024-07-16),

3. 11939383 - B7-H4 antibodies and methods and use thereof (2024-03-26),

4. 11913023 - Modified B cells and methods of use thereof (2024-02-27),

5. 11891446 - Highly potent antibodies binding to death receptor 5 (2024-02-06),

6. 10941204 - Highly potent antibodies binding to death receptor 4 (2021-03-09),

7. 10689448 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2020-06-23),

8. 10138301 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2018-11-27),

9. 9834609 - Methods of detecting a tumor expressing fibroblast growth factor receptor 2 (2017-12-05),

10. 9382324 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2016-07-05),

11. 8628778 - Humanized monoclonal antibodies to hepatocyte growth factor (2014-01-14),

12. 8603987 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2013-12-10),

13. 8101725 - Monoclonal antibodies to basic fibroblast growth factor (2012-01-24),

14. 8101723 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2012-01-24),

15. 7632926 - Humanized monoclonal antibodies to hepatocyte growth factor (2009-12-15),

Title: The Innovative Contributions of Hangil Park

Introduction

Hangil Park is a prominent inventor based in San Francisco, CA, known for his significant contributions to the field of biotechnology. With a total of 14 patents to his name, Park has made remarkable advancements in the treatment of various diseases through his innovative research.

Latest Patents

Among his latest patents, Park has developed genetically modified B cells and methods of use thereof. This invention relates to isolated modified B cells, capable of expressing a chimeric receptor, which can be utilized for treating diseases such as cancer, heart disease, and neurological disorders. Another notable patent involves B7-H4 antibodies and methods for their use, which are instrumental in detecting and treating cancer where increased B7-H4 levels are present.

Career Highlights

Throughout his career, Hangil Park has worked with several companies, including Galaxy Biotech, LLC and Walking Fish Therapeutics. His work has focused on harnessing the potential of modified B cells and antibodies to create therapeutic solutions for complex health issues.

Collaborations

Park has collaborated with notable professionals in his field, including Kyung Jin Kim and Maximiliano Vasquez. These partnerships have further enhanced his research and development efforts.

Conclusion

Hangil Park's innovative work in biotechnology continues to pave the way for new treatments and therapies. His contributions are vital in addressing some of the most challenging health conditions faced today.

Profile summary based on public USPTO records.